These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37352376)

  • 1. Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
    Nyquist MD; Coleman IM; Lucas JM; Li D; Hanratty B; Meade H; Mostaghel EA; Plymate SR; Corey E; Haffner MC; Nelson PS
    Cancer Res; 2023 Sep; 83(17):2938-2951. PubMed ID: 37352376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation.
    Vander Griend DJ; Litvinov IV; Isaacs JT
    Int J Biol Sci; 2014; 10(6):627-42. PubMed ID: 24948876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
    Chatterjee P; Schweizer MT; Lucas JM; Coleman I; Nyquist MD; Frank SB; Tharakan R; Mostaghel E; Luo J; Pritchard CC; Lam HM; Corey E; Antonarakis ES; Denmeade SR; Nelson PS
    J Clin Invest; 2019 Jul; 129(10):4245-4260. PubMed ID: 31310591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting transcription of the 8q24-MYC locus in prostate cancer recognizes the equilibration between androgen receptor direct and indirect dual-functions.
    Guo J; Wei Z; Jia T; Wang L; Nama N; Liang J; Liao X; Liu X; Gao Y; Liu X; Wang K; Fu B; Chen SS
    J Transl Med; 2023 Oct; 21(1):716. PubMed ID: 37828515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor and MYC equilibration centralizes on developmental super-enhancer.
    Guo H; Wu Y; Nouri M; Spisak S; Russo JW; Sowalsky AG; Pomerantz MM; Wei Z; Korthauer K; Seo JH; Wang L; Arai S; Freedman ML; He HH; Chen S; Balk SP
    Nat Commun; 2021 Dec; 12(1):7308. PubMed ID: 34911936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells.
    Safi R; Wardell SE; Watkinson P; Qin X; Lee M; Park S; Krebs T; Dolan EL; Blattler A; Tsuji T; Nayak S; Khater M; Fontanillo C; Newlin MA; Kirkland ML; Xie Y; Long H; Fink EC; Fanning SW; Runyon S; Brown M; Xu S; Owzar K; Norris JD; McDonnell DP
    Nat Commun; 2024 Sep; 15(1):7675. PubMed ID: 39227594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC.
    Sena LA; Kumar R; Sanin DE; Thompson EA; Rosen DM; Dalrymple SL; Antony L; Yang Y; Gomes-Alexandre C; Hicks JL; Jones T; Bowers KA; Eskra JN; Meyers J; Gupta A; Skaist A; Yegnasubramanian S; Luo J; Brennen WN; Kachhap SK; Antonarakis ES; De Marzo AM; Isaacs JT; Markowski MC; Denmeade SR
    J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36194476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer.
    Crowell PD; Giafaglione JM; Jones AE; Nunley NM; Hashimoto T; Delcourt AML; Petcherski A; Agrawal R; Bernard MJ; Diaz JA; Heering KY; Huang RR; Low JY; Matulionis N; Navone NM; Ye H; Zoubeidi A; Christofk HR; Rettig MB; Reiter RE; Haffner MC; Boutros PC; Shirihai OS; Divakaruni AS; Goldstein AS
    Cell Rep; 2023 Oct; 42(10):113221. PubMed ID: 37815914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching.
    Li Y; Zhang DY; Ren Q; Ye F; Zhao X; Daniels G; Wu X; Dynlacht B; Lee P
    Mol Cell Biol; 2012 Jul; 32(13):2454-66. PubMed ID: 22508987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA.
    Grad JM; Dai JL; Wu S; Burnstein KL
    Mol Endocrinol; 1999 Nov; 13(11):1896-911. PubMed ID: 10551783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
    Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
    FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.
    Nadiminty N; Tummala R; Liu C; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2015 Aug; 14(8):1884-95. PubMed ID: 26056150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independence of HIF1a and androgen signaling pathways in prostate cancer.
    Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
    BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
    Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
    Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
    Denmeade SR; Sena LA; Wang H; Antonarakis ES; Markowski MC
    Oncologist; 2023 Jun; 28(6):465-473. PubMed ID: 37027449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
    Nyquist MD; Ang LS; Corella A; Coleman IM; Meers MP; Christiani AJ; Pierce C; Janssens DH; Meade HE; Bose A; Brady L; Howard T; De Sarkar N; Frank SB; Dumpit RF; Dalton JT; Corey E; Plymate SR; Haffner MC; Mostaghel EA; Nelson PS
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.